mRNA-1018 for H5 Only / Moderna - LARVOL DELTA

Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults ≥18 years of age in a dose-ranging Phase 1/2 clinical study (IDWeek 2025) - No abstract available

Clinical • P1/2 data • Infectious Disease • Influenza

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1504 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1504 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1500 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases